731 related articles for article (PubMed ID: 20036643)
1. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
2. Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia.
Ojima C; Noguchi Y; Miyamoto T; Saito Y; Orihashi H; Yoshimatsu Y; Watabe T; Takayama K; Hayashi Y; Itoh F
Cancer Sci; 2020 Aug; 111(8):2954-2964. PubMed ID: 32519375
[TBL] [Abstract][Full Text] [Related]
3. Myostatin gene inactivation prevents skeletal muscle wasting in cancer.
Gallot YS; Durieux AC; Castells J; Desgeorges MM; Vernus B; Plantureux L; Rémond D; Jahnke VE; Lefai E; Dardevet D; Nemoz G; Schaeffer L; Bonnieu A; Freyssenet DG
Cancer Res; 2014 Dec; 74(24):7344-56. PubMed ID: 25336187
[TBL] [Abstract][Full Text] [Related]
4. Induction of cachexia in mice by systemically administered myostatin.
Zimmers TA; Davies MV; Koniaris LG; Haynes P; Esquela AF; Tomkinson KN; McPherron AC; Wolfman NM; Lee SJ
Science; 2002 May; 296(5572):1486-8. PubMed ID: 12029139
[TBL] [Abstract][Full Text] [Related]
5. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice.
Nakatani M; Takehara Y; Sugino H; Matsumoto M; Hashimoto O; Hasegawa Y; Murakami T; Uezumi A; Takeda S; Noji S; Sunada Y; Tsuchida K
FASEB J; 2008 Feb; 22(2):477-87. PubMed ID: 17893249
[TBL] [Abstract][Full Text] [Related]
6. Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells.
Argilés JM; Figueras M; Ametller E; Fuster G; Olivan M; de Oliveira CC; López-Soriano FJ; Isfort RJ; Busquets S
Muscle Nerve; 2008 Feb; 37(2):190-5. PubMed ID: 17912749
[TBL] [Abstract][Full Text] [Related]
7. Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein.
Li Q; Kumar R; Underwood K; O'Connor AE; Loveland KL; Seehra JS; Matzuk MM
Mol Hum Reprod; 2007 Sep; 13(9):675-83. PubMed ID: 17704537
[TBL] [Abstract][Full Text] [Related]
8. Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice.
Bonetto A; Penna F; Minero VG; Reffo P; Bonelli G; Baccino FM; Costelli P
Curr Cancer Drug Targets; 2009 Aug; 9(5):608-16. PubMed ID: 19508174
[TBL] [Abstract][Full Text] [Related]
9. The effects of an ActRIIb receptor Fc fusion protein ligand trap in juvenile simian immunodeficiency virus-infected rhesus macaques.
O'Connell KE; Guo W; Serra C; Beck M; Wachtman L; Hoggatt A; Xia D; Pearson C; Knight H; O'Connell M; Miller AD; Westmoreland SV; Bhasin S
FASEB J; 2015 Apr; 29(4):1165-75. PubMed ID: 25466897
[TBL] [Abstract][Full Text] [Related]
10. The possible role of myostatin in skeletal muscle atrophy and cachexia.
Jespersen J; Kjaer M; Schjerling P
Scand J Med Sci Sports; 2006 Apr; 16(2):74-82. PubMed ID: 16533345
[TBL] [Abstract][Full Text] [Related]
11. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice.
Murphy KT; Chee A; Gleeson BG; Naim T; Swiderski K; Koopman R; Lynch GS
Am J Physiol Regul Integr Comp Physiol; 2011 Sep; 301(3):R716-26. PubMed ID: 21677277
[TBL] [Abstract][Full Text] [Related]
12. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.
Zhou X; Wang JL; Lu J; Song Y; Kwak KS; Jiao Q; Rosenfeld R; Chen Q; Boone T; Simonet WS; Lacey DL; Goldberg AL; Han HQ
Cell; 2010 Aug; 142(4):531-43. PubMed ID: 20723755
[TBL] [Abstract][Full Text] [Related]
13. Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist.
Toledo M; Busquets S; Penna F; Zhou X; Marmonti E; Betancourt A; Massa D; López-Soriano FJ; Han HQ; Argilés JM
Int J Cancer; 2016 Apr; 138(8):2021-9. PubMed ID: 26595367
[TBL] [Abstract][Full Text] [Related]
14. Muscle and serum metabolomes are dysregulated in colon-26 tumor-bearing mice despite amelioration of cachexia with activin receptor type 2B ligand blockade.
Lautaoja JH; Lalowski M; Nissinen TA; Hentilä J; Shi Y; Ritvos O; Cheng S; Hulmi JJ
Am J Physiol Endocrinol Metab; 2019 May; 316(5):E852-E865. PubMed ID: 30860875
[TBL] [Abstract][Full Text] [Related]
15. Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.
Nissinen TA; Hentilä J; Penna F; Lampinen A; Lautaoja JH; Fachada V; Holopainen T; Ritvos O; Kivelä R; Hulmi JJ
J Cachexia Sarcopenia Muscle; 2018 Jun; 9(3):514-529. PubMed ID: 29722201
[TBL] [Abstract][Full Text] [Related]
16. Molecular, cellular and physiological investigation of myostatin propeptide-mediated muscle growth in adult mice.
Matsakas A; Foster K; Otto A; Macharia R; Elashry MI; Feist S; Graham I; Foster H; Yaworsky P; Walsh F; Dickson G; Patel K
Neuromuscul Disord; 2009 Jul; 19(7):489-99. PubMed ID: 19541486
[TBL] [Abstract][Full Text] [Related]
17. Follistatin-derived peptide expression in muscle decreases adipose tissue mass and prevents hepatic steatosis.
Nakatani M; Kokubo M; Ohsawa Y; Sunada Y; Tsuchida K
Am J Physiol Endocrinol Metab; 2011 Mar; 300(3):E543-53. PubMed ID: 21205933
[TBL] [Abstract][Full Text] [Related]
18. Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice.
Hulmi JJ; Oliveira BM; Silvennoinen M; Hoogaars WM; Pasternack A; Kainulainen H; Ritvos O
Am J Physiol Endocrinol Metab; 2013 Jul; 305(2):E171-82. PubMed ID: 23695214
[TBL] [Abstract][Full Text] [Related]
19. Embryonic overexpression of Galgt2 inhibits skeletal muscle growth via activation of myostatin signaling.
Chandraskeharan K; Martin PT
Muscle Nerve; 2009 Jan; 39(1):25-41. PubMed ID: 19086062
[TBL] [Abstract][Full Text] [Related]
20. Myostatin/activin blocking combined with exercise reconditions skeletal muscle expression profile of mdx mice.
Kainulainen H; Papaioannou KG; Silvennoinen M; Autio R; Saarela J; Oliveira BM; Nyqvist M; Pasternack A; 't Hoen PA; Kujala UM; Ritvos O; Hulmi JJ
Mol Cell Endocrinol; 2015 Jan; 399():131-42. PubMed ID: 25304272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]